WO2003101188A1 - Modele animal a pathologie liee a un stress chronique et son procede de construction - Google Patents
Modele animal a pathologie liee a un stress chronique et son procede de construction Download PDFInfo
- Publication number
- WO2003101188A1 WO2003101188A1 PCT/JP2003/006846 JP0306846W WO03101188A1 WO 2003101188 A1 WO2003101188 A1 WO 2003101188A1 JP 0306846 W JP0306846 W JP 0306846W WO 03101188 A1 WO03101188 A1 WO 03101188A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lysine
- diet
- chronic stress
- model animal
- animal
- Prior art date
Links
- 241001465754 Metazoa Species 0.000 title claims abstract description 45
- 230000037326 chronic stress Effects 0.000 title claims abstract description 43
- 238000000034 method Methods 0.000 title claims abstract description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract description 17
- 201000010099 disease Diseases 0.000 title abstract description 13
- 239000004472 Lysine Substances 0.000 claims abstract description 61
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 59
- 235000005911 diet Nutrition 0.000 claims abstract description 52
- 230000037213 diet Effects 0.000 claims abstract description 49
- 239000003814 drug Substances 0.000 claims abstract description 32
- 229940079593 drug Drugs 0.000 claims abstract description 28
- 230000002950 deficient Effects 0.000 claims abstract description 25
- 230000000694 effects Effects 0.000 claims abstract description 19
- 150000001875 compounds Chemical class 0.000 claims abstract description 14
- 208000013200 Stress disease Diseases 0.000 claims description 36
- 230000009278 visceral effect Effects 0.000 claims description 14
- 238000012216 screening Methods 0.000 claims description 10
- 230000005856 abnormality Effects 0.000 claims description 9
- 230000005176 gastrointestinal motility Effects 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 208000014540 Functional gastrointestinal disease Diseases 0.000 claims description 7
- 206010020751 Hypersensitivity Diseases 0.000 claims description 5
- 208000026935 allergic disease Diseases 0.000 claims description 5
- 230000009610 hypersensitivity Effects 0.000 claims description 5
- 230000002496 gastric effect Effects 0.000 claims description 4
- 241000283984 Rodentia Species 0.000 claims description 3
- 108010068370 Glutens Proteins 0.000 claims description 2
- 235000021312 gluten Nutrition 0.000 claims description 2
- 241000700159 Rattus Species 0.000 description 29
- 230000035882 stress Effects 0.000 description 13
- 208000002551 irritable bowel syndrome Diseases 0.000 description 12
- 235000021590 normal diet Nutrition 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000007812 deficiency Effects 0.000 description 7
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 6
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 230000008447 perception Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 5
- 229960000258 corticotropin Drugs 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 208000018522 Gastrointestinal disease Diseases 0.000 description 4
- 230000001919 adrenal effect Effects 0.000 description 4
- 239000002249 anxiolytic agent Substances 0.000 description 4
- 230000000949 anxiolytic effect Effects 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 208000004454 Hyperalgesia Diseases 0.000 description 3
- 208000035154 Hyperesthesia Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 235000012730 carminic acid Nutrition 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 210000003405 ileum Anatomy 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000000528 statistical test Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 208000011390 Rumination Syndrome Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000004676 abdominal muscle contraction Effects 0.000 description 2
- 230000037328 acute stress Effects 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- FLZQKRKHLSUHOR-UHFFFAOYSA-N alosetron Chemical compound CC1=NC=N[C]1CN1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FLZQKRKHLSUHOR-UHFFFAOYSA-N 0.000 description 2
- 229960003550 alosetron Drugs 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000001078 anti-cholinergic effect Effects 0.000 description 2
- 229940005530 anxiolytics Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 201000000117 functional diarrhea Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000009935 visceral pain Diseases 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010052813 Aerophagia Diseases 0.000 description 1
- 208000037071 Aerophagy Diseases 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000272875 Ardeidae Species 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 208000034347 Faecal incontinence Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010036772 Proctalgia Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000027520 Somatoform disease Diseases 0.000 description 1
- 241000473945 Theria <moth genus> Species 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- 238000003453 ammonium sulfate precipitation method Methods 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 208000008784 apnea Diseases 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 229940053197 benzodiazepine derivative antiepileptics Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 208000018459 dissociative disease Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000005989 gallbladder dysfunction Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 210000003903 pelvic floor Anatomy 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- DDHUTBKXLWCZCO-UHFFFAOYSA-N pinaverium Chemical compound C1=C(OC)C(OC)=CC(Br)=C1C[N+]1(CCOCCC2C3CC(C3(C)C)CC2)CCOCC1 DDHUTBKXLWCZCO-UHFFFAOYSA-N 0.000 description 1
- 229960000361 pinaverium Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940043274 prophylactic drug Drugs 0.000 description 1
- 230000001107 psychogenic effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000013285 stress animal model Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/02—Breeding vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- Patent application title Chronic stress disease model animal and method for producing the same
- the present invention provides a model animal for chronic stress disease obtained as a result of ingesting an animal with a lysine-deficient diet, a method for producing the model animal, a method for determining the effect of a drug on chronic stress disease using the model animal, Or screening method for developing a medicament for preventing and treating or treating chronic stress disease
- Drugs for treating stress-related diseases include anxiolytics (benzodiazepine derivatives, etc.), antidepressants (monoamine uptake inhibitors, tricyclics, etc.) for the purpose of alleviating psychological stressors, and digestion.
- anxiolytics benzodiazepine derivatives, etc.
- antidepressants monoamine uptake inhibitors, tricyclics, etc.
- Many drugs have been developed for vascular peristalsis and visceral pain.
- Lysine is one of the essential amino acids, and its deficiency and low 1 / have been reported to cause mental and physical disability (DA Levitsky and BJ St rupp, J. Nutr. 125 , 2212S-2220S, 1995, DA Levitsky and RH Barnes, Nature 225, 468-469, 1970, HP Chase et al., Nature 221, 554-555, 1969, PH Abelson, Science 164, 17, 1969).
- lysine itself enhances the effect of the anxiolytic diazepam in a convulsion model (Yung-Feng and G. Xue-Min, Neurochem. Res. 20, 931-937, 1995). Protection (G. Hong-Ping and K.
- the present invention aims to determine the therapeutic effect of a drug on chronic stress disease, or to develop a medicament for preventing and / or treating chronic stress disease.
- the purpose of this study is to provide a model animal that is necessary for screening drugs.
- Another object of the present invention is to provide a method for determining the effect of a drug on a chronic stress disease using the above model animal.
- Another object of the present invention is to provide a method for screening a compound effective for the prevention and / or treatment of a chronic stress disease using the above model animal.
- An object of the present invention is to provide a compound effective for preventing and / or treating a chronic stress disease obtained by using the compound.
- the present inventors have conducted intensive studies to solve the above-mentioned problems, and as a result, have found that deficiency of dietary lysine expresses a pathological condition similar to chronic stress-related disease, and completed the present invention. did.
- the present invention provides a chronic stress disorder disease model animal prepared by feeding an animal with a lysine-deficient diet.
- the present invention also provides a method for producing a chronic stress disease model animal, which comprises feeding the animal a lysine-deficient diet.
- the present invention also provides a method for judging the effect of a drug, comprising judging the effect of the drug on a chronic stress disease using the above model animal.
- the present invention also provides a method for screening a compound that is effective in preventing and / or treating chronic stress disease, characterized by using the above model animal.
- the present invention also provides a compound obtained by using the above screening method, which is effective for the prevention and / or treatment of a chronic stress disease.
- Figure 1 shows the blood corticosterone level, adrenal weight / body weight ratio of lysine-deficient rats, 6 is a graph showing measured ACTH levels in blood.
- Figure 2 is a graph showing the effect of dilatation in the colon on visceral perception threshold in lysine-deficient rats.
- - Figure 3 is a graph evaluating the effect of drugs used to treat irritable bowel syndrome on dysfunction in lysine-deficient rats.
- any animal may be used as long as it is subjected to dietary stress, and mammals such as mice, rats, gerbils, guinea pigs, egrets, bushes, cats, dogs, monkeys, etc. , And more preferably rodents, and more preferably, male Wistar rats of about 7 weeks of age.
- the chronic stress disease according to the present invention is a general term for diseases that develop due to chronic stress, and includes functional gastrointestinal diseases and diseases accompanied by similar conditions (anxiety disorder (panic disorder)).
- disorders and generalized anxiety disorders include somatoform disorders, dissociative disorders, neuropathy such as mood disorders, bulimia, anorexia nervosa, sleep disorders, glucoseuria gastroenteropathy, etc.
- neuropathy such as mood disorders, bulimia, anorexia nervosa, sleep disorders, glucoseuria gastroenteropathy, etc.
- gastrointestinal symptoms and functional gastrointestinal diseases are particularly preferred.
- Functional gastrointestinal disorders include, for example, irritable bowel syndrome, rumination syndrome, bulbar syndrome, functional heartburn, functional esophageal chest pain, functional gastrointestinal disorders, functional dysphagia, functional vomiting, and swallowing , Apnea, functional constipation, functional abdominal distension, functional abdominal pain syndrome, functional diarrhea, sphincter dysfunction, gallbladder dysfunction, levator ani muscle syndrome, functional fecal incontinence, pelvic floor coordination disorder, dissipative Anal pain, pediatric gastrointestinal dysfunction (pediatric reflux disease, childhood rumination syndrome, periodic vomiting syndrome, functional gastrointestinal disorders, irritable bowel syndrome, functional abdominal pain, paroxysmal abdominal pain, air swallowing, functional diarrhea, pediatric Dysfunction, functional constipation, functional stool storage, functional non-reserving stool incontinence, etc.) Among them, irritable bowel syndrome is particularly preferred.
- the model animal of the present invention is a chronic stress disease animal model animal.
- a chronic stress disease animal model animal As described in the literature of PBChappell et al. (J. Neuroscience, 6 (10): 2908-2914, 1986), an increase in blood ACTH and corticosterone levels was observed in an acute stress animal model. However, adrenal hypertrophy is not observed.
- the chronic stress model shows an increase in blood corticosterone level and adrenal hypertrophy, but no increase in blood ACTH level.
- a diet having a lysine content lower than that of a normal diet is 13.4 g / kg diet.
- the lysine-deficient diet used in the present invention preferably has a lysine content of 1 g / kg diet or less, more preferably 0.3 g / kg diet or less.
- a low lysine diet prepared by using wheat gluten having a low lysine content as a main raw material This includes 1/4 of the ideal demand for lysine, which can maintain weight gain in rats. In other words, it is preferable to feed less than 1/4 of the ideal demand.
- the model animal of the present invention has a pathological condition of chronic stress disease, particularly a pathological condition of functional gastrointestinal tract disease.
- the pathological condition include gastrointestinal organ unchanged, visceral hypersensitivity (JE Richter et al. Dig. Dis. Sci., 31: 131-138, 1986, WE Whitehead et al. Gastroenterology, 98: 1187-1192, 1990), gastrointestinal motility abnormalities (JE Kello et al. Gastroenterology, 98: 1208-1218, 1990), etc. It is preferable to have one, two or all of these, but it is not particularly limited to these.
- the lysine-deficient diet used is the lysine-deficient diet described above, and the period of ingestion of the lysine-deficient diet is not particularly limited, but it is preferable that the diet be continuously ingested. Ingest for 3 consecutive days Is more preferable, and it is still more preferable to make the ingestion continuously for 3 to 10 days.
- the evaluation method is based on the pathological condition of the model animal of the present invention as an index.
- the effect of the drug can be assessed, for example, for visceral hyperalgesia or gastrointestinal motility abnormalities.
- various methods used for measuring pain response using a balloon in animals can be used.
- there is a threshold measurement method using visual abdominal muscle contraction as an index but the method is not necessarily limited to this.
- a method for evaluating gastrointestinal motility abnormality a method for evaluating a defecation increase reaction is preferable, and various methods used for measuring intestinal transit ability in animals can be used. For example, there is a method using a carmine dye, but the method is not necessarily limited to ⁇ .
- the model animals used in these evaluation methods may be prepared by the above-described preparation method, and preferably, fasted on the day before the evaluation.
- model animals of the present invention to measure the effects of compounds on chronic stress diseases, particularly functional gastrointestinal diseases, and to prevent and / or treat or treat chronic stress diseases, particularly functional gastrointestinal diseases, Can be screened.
- screening is performed by determining the effect of the compound on visceral hypersensitivity and / or gastrointestinal motility abnormality in the model animal of the present invention.
- Compounds that reduce visceral hyperalgesia and gastrointestinal motility abnormalities in screening may be candidates for drugs for preventing and / or treating visceral hyperalgesia and gastrointestinal dysmotility associated with chronic stress diseases, particularly functional gastrointestinal diseases.
- a compound effective for the prevention and / or treatment of chronic stress-related diseases obtained by screening is used as a drug, it can be used as it is or as a drug known per se It is used as a pharmaceutical composition mixed with a chemically acceptable carrier, excipient and the like.
- the administration may be any of oral administration such as tablets, capsules, powders, granules and pills, and parenteral administration such as injections, syrups, ointments and suppositories. Dosage is
- the animal model for chronic stress disease of the present invention is an epoch-making model having a unique characteristic that expresses the same symptoms as chronic stress disease in humans. This is useful for determining the effect. Therefore, the present invention will dramatically advance the development of drugs for preventing and / or treating chronic stress diseases.
- Lysine content 0.3 g / kg diet or less 13.g / kg diet
- Rats 7 days after a low lysine diet tended to have increased levels of blood corticosterone, a commonly used indicator of stress exposure, compared to rats that continued to receive a normal diet. .
- rats aged 7 days on a low lysine diet had higher adrenal weight / weight compared to rats on a normal diet. The ratio increased.
- the blood ACTH level which is a regulator of corticosterone, was decreased compared to rats that continued to receive the normal diet.
- a rat fasted for one day was inserted non-invasively with a balloon catheter through the anus under mild ether anesthesia. Water was injected at a flow rate of 0.9 ml / min until the internal pressure of the Distension balloon reached 100 mmHg (cut off value), and the internal pressure of the Distension balloon at the time of visual abdominal muscle contraction was measured as the visceral perception threshold .
- the interval of stimulation into the abdominal cavity was set to 5 minutes, the visceral perception threshold was measured 5 to 8 times, and the value obtained by averaging three consecutively stable thresholds was measured as the visceral perception threshold.
- the statistical test used Student's t-te st.
- the results are shown in FIG.
- the visceral perception threshold of rats continuously fed a low lysine diet was 14.2 It was determined to be 3 ⁇ 2.17 mmHg, which was significantly lower than the visceral perception threshold (29.9 ⁇ 5.37 nnnHg) of rats continuously fed the Normal diet.
- Drugs and carmine pigment were orally administered to rats fasted for one day from the day before the start of the experiment (day 6 of the experimental diet), and the number of carmine pigment-containing feces was counted over time.
- the statistical test used Dunnett's test.
- Test drugs Diazepam (anxiolytic), Atropine (anticholinergic), Alosetron (serotonin 3 receptor antagonist: irritable bowel syndrome), Pinavepium (new evening Eve calcium antagonist: irritable bowel syndrome) ) And the results are shown in Fig. 3.
- Anxiolytics are prescribed for patients with irritable bowel syndrome because psychological stress worsens intestinal function.
- anticholinergic drugs suppress intestinal motility and secretion and have an antispasmodic action, so they are sometimes used for the treatment of irritable bowel syndrome.
- the animal model for a chronic stress disease of the present invention is an epoch-making model having characteristics unique to humans that exhibit the same symptoms as a chronic stress disease in humans.
- the operation of the present invention By using the product model, it is possible to efficiently determine the improvement effect of the drug on chronic stress disease. That is, according to the present invention, the development of a medicament for treating and / or preventing a chronic stress disease is dramatically advanced.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Environmental Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004508559A JPWO2003101188A1 (ja) | 2002-05-31 | 2003-05-30 | 慢性ストレス性疾患モデル動物及びその作製方法 |
AU2003241988A AU2003241988A1 (en) | 2002-05-31 | 2003-05-30 | Chronic stress-related disease model animal and method of constructing the same |
US10/998,832 US20050076398A1 (en) | 2002-05-31 | 2004-11-30 | Animal model of chronic stress diseases and method for producing the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-160189 | 2002-05-31 | ||
JP2002160189 | 2002-05-31 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/998,832 Continuation US20050076398A1 (en) | 2002-05-31 | 2004-11-30 | Animal model of chronic stress diseases and method for producing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003101188A1 true WO2003101188A1 (fr) | 2003-12-11 |
Family
ID=29706538
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/006846 WO2003101188A1 (fr) | 2002-05-31 | 2003-05-30 | Modele animal a pathologie liee a un stress chronique et son procede de construction |
Country Status (4)
Country | Link |
---|---|
US (1) | US20050076398A1 (ja) |
JP (1) | JPWO2003101188A1 (ja) |
AU (1) | AU2003241988A1 (ja) |
WO (1) | WO2003101188A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1707194A1 (en) * | 2004-01-23 | 2006-10-04 | Ajinomoto Co., Inc. | Stress relieving composition |
US20080010691A1 (en) * | 2005-01-28 | 2008-01-10 | Toshiyuki Funatsu | Method of Screening Therapeutic Agent for Irritable Bowel Syndrome |
CN103918606A (zh) * | 2014-05-03 | 2014-07-16 | 开阳飞腾农业开发有限公司 | 竹馏快速养殖法 |
CN111248151A (zh) * | 2020-01-19 | 2020-06-09 | 江西中医药大学 | 一种对补益类中药进行安全评价实验模型的构建方法 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102405878B (zh) * | 2011-08-03 | 2015-05-27 | 浙江工业大学 | 一种抑郁症动物模型的构建方法 |
RU2563124C1 (ru) * | 2014-04-28 | 2015-09-20 | Федеральное государственное бюджетное учреждение "Федеральный медицинский исследовательский центр психиатрии и наркологии имени В.П. Сербского" Министерства здравоохранения Российской Федерации (ФГБУ "ФМИЦПН им. В.П. Сербского" Минздрава России) | Способ диагностики шизофрении |
CN111280129A (zh) * | 2020-02-26 | 2020-06-16 | 重庆医科大学 | 一种青幼期食蟹猴抑郁模型的构建方法 |
-
2003
- 2003-05-30 AU AU2003241988A patent/AU2003241988A1/en not_active Abandoned
- 2003-05-30 WO PCT/JP2003/006846 patent/WO2003101188A1/ja active Application Filing
- 2003-05-30 JP JP2004508559A patent/JPWO2003101188A1/ja not_active Abandoned
-
2004
- 2004-11-30 US US10/998,832 patent/US20050076398A1/en not_active Abandoned
Non-Patent Citations (5)
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1707194A1 (en) * | 2004-01-23 | 2006-10-04 | Ajinomoto Co., Inc. | Stress relieving composition |
EP1707194A4 (en) * | 2004-01-23 | 2009-03-18 | Ajinomoto Kk | STRESS REDUCING COMPOSITION |
US20080010691A1 (en) * | 2005-01-28 | 2008-01-10 | Toshiyuki Funatsu | Method of Screening Therapeutic Agent for Irritable Bowel Syndrome |
CN103918606A (zh) * | 2014-05-03 | 2014-07-16 | 开阳飞腾农业开发有限公司 | 竹馏快速养殖法 |
CN111248151A (zh) * | 2020-01-19 | 2020-06-09 | 江西中医药大学 | 一种对补益类中药进行安全评价实验模型的构建方法 |
Also Published As
Publication number | Publication date |
---|---|
AU2003241988A1 (en) | 2003-12-19 |
US20050076398A1 (en) | 2005-04-07 |
JPWO2003101188A1 (ja) | 2005-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2848254T3 (en) | PYRAZOLD DERIVATIVE AND ITS USE FOR MEDICAL PURPOSES | |
KR100765579B1 (ko) | 제약학적 조합물 및 이의 위장 질병의 치료를 위한 용도 | |
US20040092511A1 (en) | Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders | |
JP2011157372A (ja) | 機能性腸障害を処置する方法 | |
US20060177381A1 (en) | Opiopathies | |
Anantharamu et al. | Naloxegol: first oral peripherally acting mu opioid receptor antagonists for opioid-induced constipation | |
WO2003101188A1 (fr) | Modele animal a pathologie liee a un stress chronique et son procede de construction | |
Radwan et al. | Is melatonin involved in the irritable bowel syndrome | |
US20200323842A1 (en) | Carbamoyl cyclohexane derivatives for treating autism spectrum disorder | |
US20050245613A1 (en) | Use of gaba-b receptor positive modulators in gastro-intestinal disorders | |
Bouchoucha et al. | Effects of oral pinaverium bromide on colonic response to food in irritable bowel syndrome patients | |
WO2020208564A1 (en) | Carbamoyl cyclohexane derivatives for treating autism spectrum disorder | |
EP2007388B1 (en) | Opiopathies | |
Nagakura et al. | The selective 5-hydroxytryptamine (5-HT) 4-receptor agonist RS67506 enhances lower intestinal propulsion in mice | |
AU674016B2 (en) | Remedy for inflammatory intestinal diseases | |
Muhammad et al. | TNBS-induced ileitis with visceral hypersensitivity in dogs. | |
CN102869645A (zh) | 用于治疗肠易激综合征的方法和组合物 | |
Stakenborg et al. | P136 ELTANEXOR, AN EXPORTIN-1 INHIBITOR, RAPIDLY DECREASES INFLAMMATION AND IMPROVES OUTCOMES IN VITRO AND IN A DSS MODEL OF IBD | |
JP2009532357A (ja) | 4−(2−フルオロフェニル)−6−メチル−2−(ピペラジン−1−イル)チエノ(2,3−d)ピリミジンの結晶形態 | |
JPWO2009078444A1 (ja) | 炎症性腸疾患の予防または治療剤 | |
Robinson et al. | Animal models of visceral pain | |
Javid et al. | Further investigation of the effects of 5-hydroxytryptamine, 8-OH-DPAT and DOI to mediate contraction and relaxation responses in the intestine and emesis in Suncus murinus | |
AHN et al. | INDEX TO VOLUMES 93, 94 AND 95 | |
JP2010241745A (ja) | 小腸粘膜障害の予防・治療薬剤としての医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004508559 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10998832 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |